The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
Open accessAbstract
OBJECTIVE: While all second-generation antipsychotics (SGAs) are promoted for having a low risk of extrapyramidal side effects (EPS), clinical observations suggest differences between the various agents. Nevertheless, this question has never been examined in a systematic review and meta-analysis of head-to-head comparisons. METHODS: We searched the register of the Cochrane schizophrenia group (last search May 2007), supplemented by MEDLINE (last search July 2009) for randomized, blinded studies comparing the following SGAs in the treatment of schizophrenia or related disorders: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, and zotepine. At least 3 reviewers extracted the data independently. The primary outcome was "use of antiparkinson medication." The results were combined in a meta-analysis. RESULTS: We included 54 studies with 116 arms. Risperidone was associated with more use of antiparkinson medication than clozapine, olanzapine, quetiapine, and ziprasidone. Ziprasidone showed more use of antiparkinson medication than olanzapine and quetiapine and zotepine more than clozapine. There was no significant difference between amisulpride and its comparators (olanzapine, risperidone, or ziprasidone). Quetiapine showed significantly less use of antiparkinson medication than the 3 other SGAs it was compared with (olanzapine, risperidone, and ziprasidone). Scale-derived data (Barnes Akathisia Scale and Simpson Angus Scale) were limited. CONCLUSIONS: Our meta-analysis demonstrates that there are differences between the SGAs in their ability to induce EPS that clinicians consider warrant treatment with antimuscarinic drugs. Even though the differences were relatively small, they might be important for individual patients and should be taken into account in drug choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings
Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.637 · Cited by 957
Marder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 759
Self-citationCorrell, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Self-citation
Cited by
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“A direct comparison between AP to calculate differences between the various AP was only presented by Rummel-Kluge, performing a head-to-head comparison [25] Leucht and colleagues [35] also showed that (i) all AP are associated with at least some weight gain compared with placebo and (ii) that olanzapine and clozapine…”
ResultSolmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2082 · Cited by 423
Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tiihonen, J. (2020) · World Psychiatry · doi:10.1002/wps.20699 · Cited by 415
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
García, S., Martínez-Cengotitabengoa, M., López-Zurbano, S., Zorrilla, I., López, P., Vieta, E., & González-Pinto, A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000523 · Cited by 360
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Manu, P., Dima, L., Shulman, M., Vancampfort, D., De Hert, M., & Correll, C. U. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12445 · Cited by 285
Llorca, P. M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., & Samalin, L. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-340 · Cited by 188
“Oral SGA induced fewer extrapyramidal side effects than oral FGA but some SGA induced more weight gain or metabolic side effects than oral FGA [41,42].”
BackgroundThe Assessment and Treatment of Antipsychotic-Induced Akathisia
Pringsheim, T., Gardner, D., Addington, D., Martino, D., Morgante, F., Ricciardi, L., Poole, N., Remington, G., Edwards, M., Carson, A., et al. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718760288 · Cited by 89
Treatment of posttraumatic stress disorder: Focus on pharmacotherapy
Ehret, M. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.11.373 · Cited by 53
“medical problems such as metabolic syndrome, hyperprolactinemia, or potential extrapyramidal effects.(28,29)”
BackgroundBerna, F., Misdrahi, D., Boyer, L., Aouizerate, B., Brunel, L., Capdevielle, D., Chereau, I., Danion, J. M., Dorey, J. M., Dubertret, C., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.10.040 · Cited by 47
Kluge, M., Himmerich, H., Wehmeier, P. M., Rummel-Kluge, C., Dalal, M., Hinze-Selch, D., Kraus, T., Dittmann, R. W., Pollmächer, T., & Schuld, A. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.12.017 · Cited by 22
Self-citationWang, X., Ye, F., Zhang, Z., Zhang, Q., & Li, G. (2025) · Medicine · doi:10.1097/md.0000000000042803 · Cited by 5
Metadata
- Authors
- Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-31
- Volume
- 38
- Issue
- 1
- Pages
- 167-177
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2101228291
- Cited by
- 272
- References
- 45
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.